RingelMD, SosaJA, BalochZ, et al.2025 American thyroid association management guidelines for adult patients with differentiated thyroid cancer. Thyroid2025;35(8):841–985; doi: 10.1177/10507256251363120
2.
SawkaAM, LakraDC, LeaJ, et al.A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol (Oxf)2008;69(3):479–490; doi: 10.1111/j.1365-2265.2008.03222.x
3.
HarlowSD, GassM, HallJE, STRAW + 10 Collaborative Group. et al.; Executive summary of the stages of reproductive aging workshop + 10: Addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab2012;97(4):1159–1168; doi: 10.1210/jc.2011-3362
4.
SalemiF, JambarsangS, KheirkhahA, et al.The best ovarian reserve marker to predict ovarian response following controlled ovarian hyperstimulation: A systematic review and meta-analysis. Syst Rev2024;13(1):303; doi: 10.1186/s13643-024-02684-0
5.
AnagnostisP, FlorouP, BosdouJK, et al.Decline in anti-Mullerian hormone concentrations following radioactive iodine treatment in women with differentiated thyroid cancer: A systematic review and meta-analysis. Maturitas2021;148:40–45; doi: 10.1016/j.maturitas.2021.04.002
6.
van VelsenEFS, VisserWE, van den BergSAA, et al.Longitudinal analysis of the effect of radioiodine therapy on ovarian reserve in females with differentiated thyroid cancer. Thyroid2020;30(4):580–587; doi: 10.1089/thy.2019.0504
7.
AdamskaA, Tomczuk-BobikP, Poplawska-KitaAB, et al.Assessment of different markers of ovarian reserve in women with papillary thyroid cancer treated with radioactive iodine. Endocr Connect2021;10(10):1283–1290; doi: 10.1530/EC-21-0187
8.
PiekMW, PostmaEL, van LeeuwaardeR, et al.The effect of radioactive iodine therapy on ovarian function and fertility in female thyroid cancer patients: A systematic review and meta-analysis. Thyroid2021;31(4):658–668; doi: 10.1089/thy.2020.0356
